Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check17 days agoChange DetectedIn Turkey, the study site list changed by removing Sarıyer and adding Yellowplace, both with postal code 34457.SummaryDifference0.0%

- Check31 days agoChange DetectedMinor site revision updated from v3.4.1 to v3.4.2; no study content, eligibility criteria, or user-facing actions were changed.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check53 days agoChange DetectedUI and metadata updates include the glossary toggle options (Show glossary, Hide glossary) and a new revision tag (Revision: v3.4.0). The page also updates timestamp-related labels (Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data) and removes older labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check60 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4, a minor metadata change with no visible impact on content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.